Immuneering Corp 8-K

What Happened

• Immuneering Corporation (IMRX) filed a Current Report on Form 8-K on May 15, 2026 to announce its financial results for the quarter ended March 31, 2026 and to provide operational updates.
• The company furnished the full text of the related press release as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: May 15, 2026 (Form 8-K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit: Press release containing the financial results and operational updates is attached as Exhibit 99.1.
• Administrative item: Item 9.01 lists the related exhibits filed with the 8-K.

Why It Matters

• Quarterly results and operational updates can affect the company’s share price and provide near‑term visibility into revenue, expenses, cash position, and program progress.
• This 8-K signals that detailed numbers and commentary are available in the press release (Exhibit 99.1); investors should read that release and any subsequent SEC filings for the specific revenue, earnings (or net loss), cash metrics, and management commentary before making investment decisions.